Farallon Capital Management LLC Grows Stock Holdings in Blueprint Medicines Co. (NASDAQ:BPMC)
Farallon Capital Management LLC Grows Stock Holdings in Blueprint Medicines Co. (NASDAQ:BPMC)
Farallon Capital Management LLC increased its stake in shares of Blueprint Medicines Co. (NASDAQ:BPMC – Get Rating) by 67.2% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,356,987 shares of the biotechnology company's stock after buying an additional 545,240 shares during the period. Farallon Capital Management LLC's holdings in Blueprint Medicines were worth $86,684,000 as of its most recent filing with the Securities and Exchange Commission.
據Blueprint Medicines Co.(納斯達克代碼:BPMC-GET Rating)在最近提交給美國證券交易委員會的信息中稱,Farallon Capital Management LLC在第一季度增持了該公司67.2%的股份。該機構投資者持有這家生物技術公司1,356,987股股票,在此期間又購買了545,240股。截至最近提交給美國證券交易委員會(Securities And Exchange Commission)的文件,Farallon Capital Management LLC持有的Blueprint Medicines價值86,68.4萬美元。
Other institutional investors have also recently added to or reduced their stakes in the company. Duality Advisers LP purchased a new stake in Blueprint Medicines during the first quarter worth about $761,000. JPMorgan Chase & Co. lifted its holdings in shares of Blueprint Medicines by 1.9% in the first quarter. JPMorgan Chase & Co. now owns 1,675,124 shares of the biotechnology company's stock valued at $107,006,000 after purchasing an additional 30,963 shares in the last quarter. Aigen Investment Management LP purchased a new stake in shares of Blueprint Medicines in the first quarter valued at about $570,000. Alliancebernstein L.P. lifted its holdings in shares of Blueprint Medicines by 7.6% in the fourth quarter. Alliancebernstein L.P. now owns 1,500,745 shares of the biotechnology company's stock valued at $160,745,000 after purchasing an additional 106,541 shares in the last quarter. Finally, Candriam Luxembourg S.C.A. lifted its holdings in shares of Blueprint Medicines by 12.6% in the fourth quarter. Candriam Luxembourg S.C.A. now owns 352,243 shares of the biotechnology company's stock valued at $37,728,000 after purchasing an additional 39,293 shares in the last quarter.
其他機構投資者最近也增持或減持了該公司的股份。Duality Advisers LP在第一季度購買了Blueprint Medicines的新股份,價值約761,000美元。摩根大通第一季度增持Blueprint Medicines股票1.9%。摩根大通目前持有這家生物技術公司1,675,124股股票,價值107,006,000美元,此前該公司在上個季度又購買了30,963股。Aigen Investment Management LP在第一季度購買了Blueprint Medicines的新股份,價值約57萬美元。聯合伯恩斯坦公司在第四季度增持了Blueprint Medicines 7.6%的股票。聯合伯恩斯坦公司現在擁有這家生物技術公司1,500,745股股票,價值160,745,000美元,上個季度又購買了106,541股。最後,Candriam盧森堡S.C.A.在第四季度增持了Blueprint Medicines 12.6%的股票。Candriam盧森堡股份有限公司現在持有這家生物技術公司352,243股,價值37,728,000美元,在上個季度又購買了39,293股。
Analyst Upgrades and Downgrades
分析師升級和下調評級
Several analysts have issued reports on the stock. The Goldman Sachs Group upped their price target on shares of Blueprint Medicines from $126.00 to $143.00 and gave the company a "buy" rating in a report on Wednesday, August 3rd. Piper Sandler reduced their price target on shares of Blueprint Medicines from $65.00 to $59.00 in a report on Tuesday, August 2nd. Morgan Stanley upped their price target on shares of Blueprint Medicines from $65.00 to $80.00 and gave the company an "equal weight" rating in a report on Friday. Credit Suisse Group upped their price target on shares of Blueprint Medicines from $80.00 to $90.00 in a report on Wednesday, September 7th. Finally, Raymond James reduced their price objective on shares of Blueprint Medicines from $133.00 to $115.00 and set a "strong-buy" rating on the stock in a research note on Wednesday, August 3rd. Two investment analysts have rated the stock with a sell rating, four have given a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, Blueprint Medicines has a consensus rating of "Moderate Buy" and a consensus price target of $92.19.
幾位分析師已經發布了關於該股的報告。在8月3日星期三的一份報告中,高盛夫婦將Blueprint Medicines的目標價從126.00美元上調至143.00美元,並給予該公司“買入”評級。派珀·桑德勒在8月2日星期二的一份報告中將Blueprint Medicines的股票目標價從65.00美元下調至59.00美元。在週五的一份報告中,摩根士丹利將藍圖醫藥的目標價從65.00美元上調至80.00美元,並給予該公司“同等權重”的評級。瑞士信貸集團在9月7日星期三的一份報告中將Blueprint Medicines的股票目標價從80.00美元上調至90.00美元。最後,雷蒙德·詹姆斯將Blueprint Medicines股票的目標價從133.00美元下調至115.00美元,並在8月3日星期三的一份研究報告中對該股設定了“強力買入”評級。兩位投資分析師對該股的評級為賣出,四位給予持有評級,七位給予買入評級,一位給予該公司股票強勢買入評級。根據MarketBeat的數據,Blueprint Medicines的共識評級為“適度買入”,共識目標價為92.19美元。
Insider Buying and Selling
內幕買賣
Blueprint Medicines Stock Performance
藍圖藥品類股表現
Shares of BPMC stock opened at $75.47 on Tuesday. Blueprint Medicines Co. has a one year low of $43.46 and a one year high of $117.86. The company has a 50 day moving average price of $63.57 and a 200 day moving average price of $60.69. The firm has a market capitalization of $4.50 billion, a price-to-earnings ratio of -6.36 and a beta of 0.78.
週二,BPMC股票開盤報75.47美元。Blueprint Medicines Co.的一年低點為43.46美元,一年高位為117.86美元。該公司的50日移動均線價格為63.57美元,200日移動均線價格為60.69美元。該公司的市值為45億美元,市盈率為-6.36倍,貝塔係數為0.78。
Blueprint Medicines (NASDAQ:BPMC – Get Rating) last issued its quarterly earnings results on Tuesday, August 2nd. The biotechnology company reported ($2.68) EPS for the quarter, missing the consensus estimate of ($2.23) by ($0.45). Blueprint Medicines had a negative return on equity of 45.89% and a negative net margin of 304.41%. The company had revenue of $36.55 million for the quarter, compared to analyst estimates of $37.61 million. During the same period last year, the company posted ($1.86) EPS. The business's revenue for the quarter was up 33.9% on a year-over-year basis. As a group, equities analysts forecast that Blueprint Medicines Co. will post -9.2 EPS for the current fiscal year.
Blueprint Medicines(納斯達克代碼:BPMC-GET Rating)最近一次發佈季度收益報告是在8月2日,星期二。這家生物技術公司公佈了本季度每股收益(2.68美元),低於普遍預期的(2.23美元)和(0.45美元)。Blueprint Medicines的淨資產回報率為負45.89%,淨利潤率為負304.41%。該公司本季度營收為3,655萬美元,而分析師預期為3,761萬美元。去年同期,該公司公佈的每股收益為1.86美元。該業務當季營收較上年同期增長33.9%。作為一個整體,股票分析師預計Blueprint Medicines Co.本財年每股收益將達到9.2歐元。
About Blueprint Medicines
關於藍圖藥品公司
(Get Rating)
(獲取評級)
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma.
BluePrint Medicines Corporation是一家精準治療公司,在美國和國際上開發針對基因定義的癌症和血液疾病的藥物。該公司正在開發用於治療全身性肥大細胞增多症(SM)和胃腸道間質瘤的AYVAKIT;用於治療非進展性肥大細胞增多症和其他肥大細胞疾病的口服可用、有效的試劑盒抑制劑BLU-263;以及用於治療肝細胞癌的口服可用且有效的抑制劑Fisogatinib。
Read More
閲讀更多內容
- Get a free copy of the StockNews.com research report on Blueprint Medicines (BPMC)
- Do These Dividend Achievers Deserve A Place In Your Portfolio?
- Darden Restaurants Takes the Low Road Against Inflation
- Why These 3 Stocks Are Off to Hot September Starts
- Inflation Doesn't Differentiate, But it's Impact Does
- 3 Downgraded Must-Have Stocks To Put On Your Watchlist
- 免費獲取StockNews.com關於藍圖藥物的研究報告(BPMC)
- 這些股息獲得者值得在你的投資組合中佔有一席之地嗎?
- 達頓餐廳走低通脹之路
- 這3只股票為何在9月火爆開盤
- 通貨膨脹沒有差別,但它的影響有差別
- 3只被降級的必備股票放在你的觀察名單上
Want to see what other hedge funds are holding BPMC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Blueprint Medicines Co. (NASDAQ:BPMC – Get Rating).
想看看其他對衝基金持有BPMC的情況嗎?訪問HoldingsChannel.com獲取Blueprint Medicines Co.(納斯達克代碼:BPMC-GET Rating)的最新13F申報文件和內幕交易信息。
Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
接受藍圖藥物日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Blueprint Medicines和相關公司的最新新聞和分析師評級的每日摘要。